Class I PI3 kinase inhibition by the pyridinylfuranopyrimidine inhibitor PI-103 enhances tumor radiosensitivity. - Wikidata - wikimedia - TriplyDB

Class I PI3 kinase inhibition by the pyridinylfuranopyrimidine inhibitor PI-103 enhances tumor radiosensitivity.

Class I PI3 kinase inhibition by the pyridinylfuranopyrimidine inhibitor PI-103 enhances tumor radiosensitivity.

http://www.wikidata.org/entity/Q39960673

about

Updates of mTOR inhibitors Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations.Judicious Toggling of mTOR Activity to Combat Insulin Resistance and Cancer: Current Evidence and Perspectives PI3Kp110-, Src-, FAK-dependent and DOCK2-independent migration and invasion of CXCL13-stimulated prostate cancer cells Radiosensitization of epidermal growth factor receptor/HER2-positive pancreatic cancer is mediated by inhibition of Akt independent of ras mutational status.Tumor vascular changes mediated by inhibition of oncogenic signaling.Modulating tumor vasculature through signaling inhibition to improve cytotoxic therapy.PI3K Inhibition Augments the Therapeutic Efficacy of a 3a-aza-Cyclopenta[α]indene Derivative in Lung Cancer Cells A high content clonogenic survival drug screen identifies mek inhibitors as potent radiation sensitizers for KRAS mutant non-small-cell lung cancer Akt activation is a common event in pediatric malignant gliomas and a potential adverse prognostic marker: a report from the Children's Oncology Group.AKT regulates NPM dependent ARF localization and p53mut stability in tumors.IL-6-induced epithelial-mesenchymal transition promotes the generation of breast cancer stem-like cells analogous to mammosphere cultures.A bioinformatics filtering strategy for identifying radiation response biomarker candidates.Targeting the RTK-PI3K-mTOR axis in malignant glioma: overcoming resistance.Silencing of microRNA-21 confers radio-sensitivity through inhibition of the PI3K/AKT pathway and enhancing autophagy in malignant glioma cell lines.Chloroquine or chloroquine-PI3K/Akt pathway inhibitor combinations strongly promote γ-irradiation-induced cell death in primary stem-like glioma cells NVP-BEZ235, a novel dual PI3K/mTOR inhibitor, enhances the radiosensitivity of human glioma stem cells in vitro.Hypoxia-inducible factor in thyroid carcinoma Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health.Hypoxia-induced p53 modulates both apoptosis and radiosensitivity via AKT Novel therapies in glioblastoma.The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy Inhibition of autophagy as a strategy to augment radiosensitization by the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation.High-density and very-low-density lipoprotein have opposing roles in regulating tumor-initiating cells and sensitivity to radiation in inflammatory breast cancer.Rationale-based therapeutic combinations with PI3K inhibitors in cancer treatment PI3K signaling in glioma--animal models and therapeutic challenges Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma.High linear-energy-transfer radiation can overcome radioresistance of glioma stem-like cells to low linear-energy-transfer radiation.Radiosensitising agents for the radiotherapy of cancer: novel molecularly targeted approaches.Modulating the tumor microenvironment to increase radiation responsiveness.Cell signalling and radiation survival: the impact of protein phosphatases.Novel PI3K and mTOR Inhibitor NVP-BEZ235 Radiosensitizes Breast Cancer Cell Lines under Normoxic and Hypoxic Conditions.Profiling of phospho-AKT, phospho-mTOR, phospho-MAPK and EGFR in non-small cell lung cancer.The tumor microenvironment in non-small-cell lung cancer MicroRNAs involved in the EGFR/PTEN/AKT pathway in gliomas.Current development of the second generation of mTOR inhibitors as anticancer agents.The impact of tumor microenvironment on cancer treatment and its modulation by direct and indirect antivascular strategies.Microenvironment and radiation therapy The Biological Role of PI3K Pathway in Lung Cancer.

P2860

Q24607170-F27C77D3-7A79-430C-96AE-4AC403F89B8C Q27853245-63DC8A31-FEDD-4473-8D4B-01FC4E23DCAF Q28071388-7787F3C3-029B-405F-A5FE-E3895D1C14A0 Q28395725-830BB8C3-9E3C-40CE-99FD-79029D5A6286 Q33638654-500A341D-6B16-4CE8-ABF6-76C5F31709C7 Q33671385-2A755000-77CA-4972-AA63-FBAA5DD4AFC3 Q33733303-4002CB44-C2AA-4654-97DE-15BEEEAEB69F Q33912340-DEF58F35-B5AA-455E-8188-AE7108F8B2FA Q33946208-9FE5E1EC-87F3-4F1A-A514-E492CA6795A1 Q34196216-A40A2E6A-4061-4C19-BABF-A79EB12DABFC Q34227622-1A435BC0-982B-43FC-A983-8B8F4004EB97 Q34237510-346BEE24-122F-4B13-B153-E8B9CF862ACF Q34328033-3C88D5DE-2A18-4831-8263-534A02655D56 Q34447846-398B2493-4045-4A6E-BAE9-2B51CACB753D Q34450866-45253651-AD46-4CB9-9A3B-33C2BC8AA5D1 Q34455213-4A1BC872-C0E9-4C7A-856E-CF8A290D1BB9 Q34679652-59B21207-91A5-44E2-8E6F-80575B328B1A Q35099457-7036633D-3882-4F38-9DBC-C597C1B2B567 Q35679353-2BF4E030-2171-4B06-A277-64B67824C3FC Q35836156-11C8A063-7127-46E8-947E-92901BFB2DA5 Q35864136-1CF4417D-90FB-4A6C-9708-9F6200E6077D Q36289912-03968CE0-9727-414C-9E78-387E7096A422 Q36412815-D0715288-C38D-48A3-8C1F-8EA217A40D9E Q36525188-A7F05FD1-3686-4D40-862D-EEDD303205F2 Q36710185-94C5F7B3-47B8-43D5-B93E-7BF9FBED6FEA Q36997524-A5EF3D92-1F2C-41FC-B7CD-049CBA858A5A Q37039348-8136578C-5CAE-492D-98F3-DBC40379A322 Q37164133-379FD5C2-B633-4FB9-8993-03071D07874B Q37450669-F41C7C27-A93D-4692-A020-9B3E95ED94A0 Q37489947-271445B0-7475-4888-80A8-EEFB51F1C79B Q37613364-C98DF529-926F-4696-BA9B-01CBC8F3C6A0 Q37628726-7EDEFD7E-D555-409F-9A18-2DE8F68F4416 Q37660260-10A0A8CC-04B9-4189-AC92-1D48346D2F81 Q37733727-D4636DCE-32A6-46C8-A90C-704DBB5B3099 Q37777872-50E8D369-1D34-4447-840C-83D029F9FCF7 Q37917655-ED259A6E-1BA1-4006-9990-8754DB0CC524 Q37953476-C5BB03B3-0C58-423C-AC92-E2647118D744 Q38028791-9BF803F8-CA3B-4172-B4EB-0AA3109D72E8 Q38091084-4EFAB179-6A2E-4571-9DCA-1897370132DA Q38166599-B959EB46-CCC5-4454-8D00-8D3CAC692AAE

P2860

Class I PI3 kinase inhibition by the pyridinylfuranopyrimidine inhibitor PI-103 enhances tumor radiosensitivity.

http://www.wikidata.org/entity/Q39960673

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh

2008年學術文章

@zh-hant

name

Class I PI3 kinase inhibition ...... hances tumor radiosensitivity.

@en

Class I PI3 kinase inhibition ...... hances tumor radiosensitivity.

@nl

type

label

Class I PI3 kinase inhibition ...... hances tumor radiosensitivity.

@en

Class I PI3 kinase inhibition ...... hances tumor radiosensitivity.

@nl

prefLabel

Class I PI3 kinase inhibition ...... hances tumor radiosensitivity.

@en

Class I PI3 kinase inhibition ...... hances tumor radiosensitivity.

@nl

P1433

Q39960673-58C02CEF-0FA4-453B-B7C4-B44FE27A85A7

P1476

Q39960673-26406C7F-1CE3-4E40-9B44-492E042A4D18

P2093

Q39960673-03A2BCCC-7077-4BBE-8135-64E5B1F793AD

Q39960673-495DF10A-F1CA-4983-8E35-2F7C8B970A54

Q39960673-5FCE5F29-B24B-4615-BBA3-8A582683500B

Q39960673-6CF058D7-47A4-4608-AEB8-A70193A50C4D

Q39960673-7FB608AC-2260-46A7-A587-6C18EBD8A473

Q39960673-9D379C51-3251-4F3B-8EBA-4D16C6423FD6

Q39960673-B2B4DBB0-0022-4282-99B1-2CC5EFC369DC

Q39960673-BC8283BA-5968-4731-A32B-EE38F2B1F174

Q39960673-E046A85A-1500-42EE-BF67-0A03B05157EB

P304

Q39960673-370DBFF2-E0E3-4D72-8322-B285A9F5E3DB

P31

Q39960673-531055C6-85A9-4B8B-93ED-017D18F55648

P356

Q39960673-69B9F45C-4A62-4E69-A6CF-FD5E40A3E964

P407

Q39960673-F59BDD5D-877B-4B3E-9752-1EB323DE9945

P433

Q39960673-DF8DEFA7-9F44-401E-AF34-39B0F56BF39B

P478

Q39960673-5E496649-6926-4230-B9F9-8EC1407ACF59

P50

Q39960673-89AE9F8B-923D-4D9F-893B-A9175D666E80

P577

Q39960673-C1913C75-965F-4467-8334-D94357C563F8

P698

Q39960673-28530BD7-E792-4CB4-9310-CB1D6049185E

P356

0008-5472.CAN-08-0757

P1433

Cancer Research

P1476

Class I PI3 kinase inhibition ...... nhances tumor radiosensitivity

@en

P2093

Eric J Bernhard

http://www.w3.org/2001/XMLSchema#string

Jane Harper

http://www.w3.org/2001/XMLSchema#string

Julie Diplexcito

http://www.w3.org/2001/XMLSchema#string

Keith Cengel

http://www.w3.org/2001/XMLSchema#string

Oliver Sampson

http://www.w3.org/2001/XMLSchema#string

Peter O'Neill

http://www.w3.org/2001/XMLSchema#string

Remko Prevo

http://www.w3.org/2001/XMLSchema#string

Sonal Patel

http://www.w3.org/2001/XMLSchema#string

W Gillies McKenna

http://www.w3.org/2001/XMLSchema#string

P304

5915-5923

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-08-0757

http://www.w3.org/2001/XMLSchema#string

P407

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

68

http://www.w3.org/2001/XMLSchema#string

P50

P577

2008-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18632646

http://www.w3.org/2001/XMLSchema#string